Get the Stockscreener App
11.94
1.81%
-0.22
Contineum Therapeutics Inc stock is traded at $11.94, with a volume of 313.46K.
It is down -1.81% in the last 24 hours and down -7.15% over the past month.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.
See More
Previous Close:
$12.16
Open:
$12.3
24h Volume:
313.46K
Relative Volume:
1.19
Market Cap:
$446.39M
Revenue:
$50.00M
Net Income/Loss:
$-58.44M
P/E Ratio:
-6.1146
EPS:
-1.9527
Net Cash Flow:
$-57.73M
1W Performance:
+0.67%
1M Performance:
-7.15%
6M Performance:
+4.83%
1Y Performance:
+227.12%
1-Day Range:
$11.57
$12.67
1-Week Range:
$11.57
$13.32
52-Week Range:
$3.69
$16.33
Contineum Therapeutics Inc Stock (CTNM) Company Profile
Name
Contineum Therapeutics Inc
Sector
Industry
Phone
(858) 333-5280
Address
3565 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO
Compare CTNM vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTNM
Contineum Therapeutics Inc
|
11.94 | 446.39M | 50.00M | -58.44M | -57.73M | -1.9527 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Contineum Therapeutics Inc Stock (CTNM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-13-25 | Initiated | Leerink Partners | Outperform |
| Sep-25-25 | Initiated | Leerink Partners | Outperform |
| Jun-20-25 | Initiated | William Blair | Outperform |
| Oct-22-24 | Initiated | Robert W. Baird | Outperform |
| Apr-30-24 | Initiated | Morgan Stanley | Overweight |
| Apr-30-24 | Initiated | RBC Capital Mkts | Outperform |
| Apr-30-24 | Initiated | Stifel | Buy |
View All
Contineum Therapeutics Inc Stock (CTNM) Latest News
Contineum Therapeutics Inc (CTNM) Valuation: PE, PB & Fair Value Analysis - TradingKey
Contineum Therapeutics Inc (CTNM) Institutional Confidence - TradingKey
Contineum Therapeutics Inc (CTNM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Contineum Therapeutics Inc (CTNM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Contineum Therapeutics Inc - TradingKey
Contineum Therapeutics Inc (CTNM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Contineum Therapeutics (CTNM) Slides 2.44% as Resistance Holds FirmIntraday Trade Ideas - newsline.com
Number of shareholders of Contineum Therapeutics, Inc. – NASDAQ:CTNM - TradingView
CTNM Q1 2026 Earnings: Narrower Loss Surprises as Pipeline AdvancesEBITDA Analysis - newsline.com
CTNM Q1 2026 Earnings: Narrower-than-Expected Loss Surprises MarketsProfit Announcement - newsline.com
CTNM: PIPE-791 advances in IPF with strong differentiation, robust pipeline, and solid financial runway - TradingView
CTNM: PIPE-791 advances in IPF with best-in-class potential, strong safety, and robust clinical momentum - TradingView
Are Medical Stocks Lagging Adagene (ADAG) This Year? - Yahoo Finance
Contineum Therapeutics CSO Daniel Lorrain sells $54,862 in stock - Investing.com
Contineum Therapeutics (CTNM) CSO sells 4,170 shares under 10b5-1 plan - Stock Titan
CTNM insider 10b5-1 sales recorded by Morgan Stanley (CTNM) - Stock Titan
Contineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference - Weekly Voice
CTNM Q1 2026 Earnings: Narrower-Than-Expected Loss as Clinical Pipeline AdvancesEarnings Turnaround - newsline.com
Contineum Therapeutics, Inc.Common stock (CTNM) Stock Price, News, Quote & History - FinancialContent
Contineum Therapeutics (CTNM) Retreats 1.08% – Key Support Level in FocusModified Schiff - The Legal Advocate
Contineum Therapeutics Inc. (CTNM) Q1 2026 Earnings: Narrower Loss Beats ExpectationsEarnings Beat Alert - newsline.com
Wall Street Analysts Think Contineum Therapeutics, Inc. (CTNM) Could Surge 49.21%: Read This Before Placing a Bet - MSN
CTNM Q1 2026 Earnings: Narrower Loss Beats Estimates as Pre-Revenue Biotech Maintains DisciplineFinal Results - The Legal Advocate
Contineum Therapeutics (CTNM) Declines 3.55%, Testing Key Support at $13.17Swing Trade Setups - Newser
Wall Street Analysts See a 59.96% Upside in Contineum Therapeutics, Inc. (CTNM): Can the Stock Really Move This High? - Yahoo Finance Singapore
Contineum Therapeutics Inc. (CTNM) Q1 2026 Earnings: Clinical-Stage Biotech Reports Narrower Loss, Shares DipFinancial Data - newsline.com
CTNM Q1 2026 Earnings: Narrower-than-Expected Loss Drives Strong EPS Surprise, but Shares SlipExpert Market Insights - Newser
CTNM Q1 2026 Earnings: Narrowed Loss Exceeds Expectations as Pipeline AdvancesPre-Announcement Alert - newsline.com
CTNM Q1 2026 Earnings: Significant EPS Beat Amid Pipeline Progress, Stock Slightly DownViral Trade Signals - Newser
Contineum Therapeutics Touts PIPE-791 IPF Focus as Pain Data Hint at Wider Potential - Yahoo Finance
CTNM Q1 2026 Earnings: EPS Surprise Beats Estimates, Stock Rises Amid R&D ProgressTangible Book Value - The Legal Advocate
Contineum Therapeutics Stock Edges Higher As PIPE-791 Pain Data Clears Safety Bar - MSN
RA Capital affiliates report 1.296M shares of Contineum (CTNM) - Stock Titan
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year? - Yahoo Finance
Balyasny Group (CTNM) reports 2.42M shares via ADMF, ~7.40% stake - Stock Titan
Morgan Stanley Raises Price Target on Contineum Therapeutics to $16 From $14, Keeps Equalweight Rating - Moomoo
Contineum Therapeutics, Inc. Stock 12‑Month Price Target Raised to $22.33, Implies 58% Upside - TradingView
Contineum Therapeutics to Present at the 2026 RBC Capital Markets Global Healthcare Conference - BioSpace
Stream Contineum’s 2026 RBC Global Healthcare Conference talk live - Stock Titan
Ring Energy Announces Proposed Public Offering of Common Stock - Weekly Voice
TradingKey - TradingKey
Contineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International Conference - BioSpace
Stifel Nicolaus Remains a Buy on Contineum Therapeutics, Inc. Class A (CTNM) - The Globe and Mail
RBC Capital Maintains Contineum Therapeutics (CTNM) Outperform Recommendation - MSN
Contineum Therapeutics, Inc. (NASDAQ:CTNM) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Contineum Therapeutics Inc Stock (CTNM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):